March 30, 2017 / 4:47 PM / a year ago

BRIEF-Genmab A/S says Phase II study in NHL will not proceed

March 30 (Reuters) - Genmab A/S :

* Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial

* Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed

* Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned

* Genmab says announcement has no impact on other ongoing or planned studies with daratumumab

* Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab

* Study will not proceed to stage 2 based on results of a data review

* Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn’t reach predefined ORR futility thresholds

* In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below